case_images: PMC11319124_01
case_images: Timeline of infections and therapeutic outcomes. The patient experienced five infectious events under the pralsetinib therapy with oncologic progression during pralsetinib discontinuation. The patient experienced two infectious events at a reduced dose of 300 mg. M+, months since pralsetinib initiation.
case_images: fmed-11-1402902-g001.jpg
case_images: PMC11319124_01_fmed-11-1402902-g001.jpg
case_images: fig1
case_images: Notably, the computational tomodensitometry (CT) performed to diagnose septic embolisms also reported a tumor partial response (PR), according to RECIST (Figure 1). Finally, the patient presented with liver progression on 30 June 2023, and pralsetinib was definitively discontinued (Figure 1).